Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds

Liqun Huang, Gerardo Mackenzie, Yu Sun, Nengtai Ouyang, Gang Xie, Kvetoslava Vrankova, Despina Komninou, Basil Rigas

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Nonsteroidal anti-inflammatory drugs (NSAID) exhibit antineoplastic properties, but conventional NSAIDs do not fully meet safety and efficacy criteria for use as anticancer agents. In this study, we evaluated the chemotherapeutic efficacy of 5 novel phospho-NSAIDs, each of which includes in addition to the NSAID moiety a diethylphosphate linked through a butane moiety. All 5 compounds inhibited the growth of human breast, colon, and pancreatic cancer cell lines with micromolar potency. In vivo investigations confirmed the antitumor activity of phospho-aspirin (PA) and phospho-sulindac (PS) in inhibiting tumor growth in established human xenograft models, in which cell proliferation was suppressed and apoptosis enhanced in the absence of detectable animal toxicity. Notably, all of the phospho-NSAIDs tested induced reactive oxygen and nitrogen species in cultured cells, with PA and PS inducing detectable levels of oxidative stress in vivo that were associated positively with apoptosis and negatively with proliferation. Potentially explaining these effects, all of the phospho-NSAIDs tested also inhibited the thioredoxin system and the redox sensitive transcription factor NF-κB. Taken together, our findings show the strong anticancer efficacy and promising safety of phospho-NSAIDs in preclinical models of breast, colon, and pancreatic cancer, suggesting further evaluation as anticancer agents.

Original languageEnglish (US)
Pages (from-to)7617-7627
Number of pages11
JournalCancer Research
Volume71
Issue number24
DOIs
StatePublished - Dec 15 2011
Externally publishedYes

Fingerprint

Non-Steroidal Anti-Inflammatory Agents
Anti-Inflammatory Agents
Antineoplastic Agents
Sulindac
Pharmaceutical Preparations
Pancreatic Neoplasms
Colonic Neoplasms
Aspirin
Apoptosis
Breast Neoplasms
Safety
Reactive Nitrogen Species
Thioredoxins
Growth
Heterografts
Oxidation-Reduction
Cultured Cells
Reactive Oxygen Species
Oxidative Stress
Transcription Factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. / Huang, Liqun; Mackenzie, Gerardo; Sun, Yu; Ouyang, Nengtai; Xie, Gang; Vrankova, Kvetoslava; Komninou, Despina; Rigas, Basil.

In: Cancer Research, Vol. 71, No. 24, 15.12.2011, p. 7617-7627.

Research output: Contribution to journalArticle

Huang, Liqun ; Mackenzie, Gerardo ; Sun, Yu ; Ouyang, Nengtai ; Xie, Gang ; Vrankova, Kvetoslava ; Komninou, Despina ; Rigas, Basil. / Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. In: Cancer Research. 2011 ; Vol. 71, No. 24. pp. 7617-7627.
@article{fdb48a1d002f413a9b34e82a32a7638d,
title = "Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds",
abstract = "Nonsteroidal anti-inflammatory drugs (NSAID) exhibit antineoplastic properties, but conventional NSAIDs do not fully meet safety and efficacy criteria for use as anticancer agents. In this study, we evaluated the chemotherapeutic efficacy of 5 novel phospho-NSAIDs, each of which includes in addition to the NSAID moiety a diethylphosphate linked through a butane moiety. All 5 compounds inhibited the growth of human breast, colon, and pancreatic cancer cell lines with micromolar potency. In vivo investigations confirmed the antitumor activity of phospho-aspirin (PA) and phospho-sulindac (PS) in inhibiting tumor growth in established human xenograft models, in which cell proliferation was suppressed and apoptosis enhanced in the absence of detectable animal toxicity. Notably, all of the phospho-NSAIDs tested induced reactive oxygen and nitrogen species in cultured cells, with PA and PS inducing detectable levels of oxidative stress in vivo that were associated positively with apoptosis and negatively with proliferation. Potentially explaining these effects, all of the phospho-NSAIDs tested also inhibited the thioredoxin system and the redox sensitive transcription factor NF-κB. Taken together, our findings show the strong anticancer efficacy and promising safety of phospho-NSAIDs in preclinical models of breast, colon, and pancreatic cancer, suggesting further evaluation as anticancer agents.",
author = "Liqun Huang and Gerardo Mackenzie and Yu Sun and Nengtai Ouyang and Gang Xie and Kvetoslava Vrankova and Despina Komninou and Basil Rigas",
year = "2011",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-11-2349",
language = "English (US)",
volume = "71",
pages = "7617--7627",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds

AU - Huang, Liqun

AU - Mackenzie, Gerardo

AU - Sun, Yu

AU - Ouyang, Nengtai

AU - Xie, Gang

AU - Vrankova, Kvetoslava

AU - Komninou, Despina

AU - Rigas, Basil

PY - 2011/12/15

Y1 - 2011/12/15

N2 - Nonsteroidal anti-inflammatory drugs (NSAID) exhibit antineoplastic properties, but conventional NSAIDs do not fully meet safety and efficacy criteria for use as anticancer agents. In this study, we evaluated the chemotherapeutic efficacy of 5 novel phospho-NSAIDs, each of which includes in addition to the NSAID moiety a diethylphosphate linked through a butane moiety. All 5 compounds inhibited the growth of human breast, colon, and pancreatic cancer cell lines with micromolar potency. In vivo investigations confirmed the antitumor activity of phospho-aspirin (PA) and phospho-sulindac (PS) in inhibiting tumor growth in established human xenograft models, in which cell proliferation was suppressed and apoptosis enhanced in the absence of detectable animal toxicity. Notably, all of the phospho-NSAIDs tested induced reactive oxygen and nitrogen species in cultured cells, with PA and PS inducing detectable levels of oxidative stress in vivo that were associated positively with apoptosis and negatively with proliferation. Potentially explaining these effects, all of the phospho-NSAIDs tested also inhibited the thioredoxin system and the redox sensitive transcription factor NF-κB. Taken together, our findings show the strong anticancer efficacy and promising safety of phospho-NSAIDs in preclinical models of breast, colon, and pancreatic cancer, suggesting further evaluation as anticancer agents.

AB - Nonsteroidal anti-inflammatory drugs (NSAID) exhibit antineoplastic properties, but conventional NSAIDs do not fully meet safety and efficacy criteria for use as anticancer agents. In this study, we evaluated the chemotherapeutic efficacy of 5 novel phospho-NSAIDs, each of which includes in addition to the NSAID moiety a diethylphosphate linked through a butane moiety. All 5 compounds inhibited the growth of human breast, colon, and pancreatic cancer cell lines with micromolar potency. In vivo investigations confirmed the antitumor activity of phospho-aspirin (PA) and phospho-sulindac (PS) in inhibiting tumor growth in established human xenograft models, in which cell proliferation was suppressed and apoptosis enhanced in the absence of detectable animal toxicity. Notably, all of the phospho-NSAIDs tested induced reactive oxygen and nitrogen species in cultured cells, with PA and PS inducing detectable levels of oxidative stress in vivo that were associated positively with apoptosis and negatively with proliferation. Potentially explaining these effects, all of the phospho-NSAIDs tested also inhibited the thioredoxin system and the redox sensitive transcription factor NF-κB. Taken together, our findings show the strong anticancer efficacy and promising safety of phospho-NSAIDs in preclinical models of breast, colon, and pancreatic cancer, suggesting further evaluation as anticancer agents.

UR - http://www.scopus.com/inward/record.url?scp=84255170384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84255170384&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-2349

DO - 10.1158/0008-5472.CAN-11-2349

M3 - Article

C2 - 22025561

AN - SCOPUS:84255170384

VL - 71

SP - 7617

EP - 7627

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -